Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Neurocritical Care|September 15, 2010
Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trialsR Loch Macdonald, Randall T Higashida, Emanuela Keller, et al.Acta Neurochirurgica. Supplement|August 15, 2012
Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2)R Loch Macdonald, Randall T Higashida, Emanuela Keller, et al.Journal of the American College of Cardiology|July 10, 2003
Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failureGuillermo Torre-Amione, James B Young, Wilson S Colucci, et al.The Lancet. Neurology|June 7, 2011
Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2)R Loch Macdonald, Randall T Higashida, Emanuela Keller, et al.Stroke|March 10, 2012
Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coilingR Loch Macdonald, Randall T Higashida, Emanuela Keller, et al.European Journal of Heart Failure|August 11, 2004
The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failureGad Cotter, Edo Kaluski, Karl Stangl, et al.Cardiology|September 14, 2011
Neurohormonal activation in acute heart failure: results from VERITASOlga Milo-Cotter, Beth Cotter-Davison, Carlo Lombardi, et al.American Heart Journal|August 9, 2005
Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS)John R Teerlink, John J V McMurray, Robert C Bourge, et al.JAMA|November 8, 2007
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trialsJohn J V McMurray, John R Teerlink, Gadi Cotter, et al.The New England Journal of Medicine|December 25, 2015
Selexipag for the Treatment of Pulmonary Arterial HypertensionOlivier Sitbon, Richard Channick, Kelly M Chin, et al.Pageof 4